VK2735 is a dual agonist of the GLP-1 receptor and GIP receptor, with a similar mechanism of action as tirzepatide, which acts on the same receptors. It is injectable and is being developed by Viking Therapeutics. From Wikipedia
Shares of Novo Nordisk and Eli Lilly fall as Viking Therapeutics announces progression to phase 3 trials for its promising obesity treatment VK2735.
